1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia.
14 patients with essential thrombocythemia (ET) and 1 patient with agnogenic myeloid metaplasia received (1-(2-chloroethyl)-cyclohexyl-nitrosourea (CCNU), 80 mg/m2, p.o., in a single dose once a month up to three times. Remission was achieved in 13 patients (86.6%) and easily maintained by low-dose busulfan (2 mg twice a week). The data on the treatment of ET reported in the literature have been reviewed and compared to our results.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use; D002066:Busulfan / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced; D008130:Lomustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000188:drug therapy; D013922:Thrombocytosis / Q000188:drug therapy*
D000477:Alkylating Agents; D009607:Nitrosourea Compounds; D010761:Phosphorus Radioisotopes; D008130:Lomustine; D002066:Busulfan